Curis, Inc. (NASDAQ: CRIS), a drug development company, is focused on utilizing its innovative signaling pathway drug technologies to discover new targeting small molecule drug candidates for cancer. Through the expansion of its drug development efforts in the field of cancer, the company is building upon its previous experiences in targeting signaling pathways to develop next generation targeted cancer therapies. For further information, visit the Company’s web site at www.curis.com.
- 18 years ago
QualityStocks
Curis, Inc. (NASDAQ: CRIS)
Tags Rodman & Renshaw
Related Post
-
HeartBeam Inc. (NASDAQ: BEAT) Tackles Heart Disease with Next-Generation ECG Solutions
Cardiovascular disease remains the leading cause of death in the United States. One of the…
-
Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) Positions for Next Phase of Commercial Space Infrastructure Expansion
Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.…
-
QualityStocksNewsBreaks – Information Services Group (NASDAQ: III) Rings Nasdaq Closing Bell To Mark 20th Anniversary
Information Services Group (NASDAQ: III) will mark its 20th anniversary by ringing the closing bell on May 5, 2026, at…